Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $15.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 190.70% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Stock Down 1.0 %

NASDAQ:COYA opened at $5.16 on Wednesday. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.69. The company has a fifty day simple moving average of $6.96 and a two-hundred day simple moving average of $6.64. The company has a market cap of $86.21 million, a price-to-earnings ratio of -7.94 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. On average, analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Insider Activity

In related news, CEO Arun Swaminathan bought 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, with a total value of $36,700.00. Following the transaction, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at approximately $36,700. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 9,510 shares of company stock worth $69,615. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the 3rd quarter worth $169,000. Renaissance Technologies LLC acquired a new stake in Coya Therapeutics during the 2nd quarter worth approximately $101,000. Gilbert & Cook Inc. purchased a new position in shares of Coya Therapeutics in the 2nd quarter valued at approximately $61,000. Finally, Geode Capital Management LLC raised its stake in shares of Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.